Gerdes S, Bräu B, Hoffmann M, et al. - Guselkumab proved to be effective for psoriasis in the real-world setting, as measured by health-related quality of life (HRQoL) and skin improvements, even in cases exhibiting a high burden of disease and those treated with multiple biologic therapies. No new safety signals were noted.

• This ongoing prospective, noninterventional, long-term, German multicenter study (PERSIST) involves 303 patients with moderate-to-severe psoriasis; 51.2% (n = 155) had received ≥1 prior biologic therapy.

• After 28 weeks of guselkumab use, reduction in the mean Dermatology Life Quality Index (DLQI) score to 2.8 was evident, and DLQI ≤ 1 was achieved by 56.8% of patients (n = 150).

• Improvements in mean Psoriasis Symptoms and Signs Diary symptom and sign scores were noted, with reductions to 12.5 and 15.9, respectively.

• Psoriasis Area Severity Index (PASI 90) response at week 28 was 55.3%; significant improvement was seen in cases with psoriasis in difficult-to-treat areas.